Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: A focus on methodological issues

Drug Safety

Volumn 34, Issue 11, 2011, Pages 1027-1048

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Citalopram; Clinical trial design; Congenital abnormalities; Depression; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Postmarketing surveillance; Pregnancy; Serotonin uptake inhibitors; Sertraline; Teratogenesis

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONGENITAL MALFORMATION; DEPRESSION; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; NERVE CELL DIFFERENTIATION; PREGNANCY OUTCOME; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; TREATMENT DURATION; TREATMENT OUTCOME;

DEPRESSIVE DISORDER; FEMALE; HUMANS; PAROXETINE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80053907631     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11593130-000000000-00000     Document Type: Review

References (115)

1. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157 (12): 1933-40
2. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103 (4): 698-709 (Pubitemid 40459031)
3. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand 2000; 101 (403 Suppl.): 26-34S
4. O'Hara MW, Swain AM. Rates and risk of postpartum depression-a meta-analysis. Int Rev Psychiatry 1996; 8 (1): 37-54
5. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49 (11): 726-35 (Pubitemid 40100521)
6. Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005; 51 (8): 1087-93 (Pubitemid 41167571)
7. Sugiura-Ogasawara M, Furukawa TA, Nakano Y, et al. Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Hum Re-prod 2002; 17 (10): 2580-4 (Pubitemid 35174107)
8. Nelson DB, McMahon K, Joffe M, et al. The effect of de-pressive symptoms and optimism on the risk of spontaneous abortion among innercity women. J Womens Health (Larchmt) 2003; 12 (6): 569-76 (Pubitemid 37098965)
9. Paarlberg KM, Vingerhoets AD, Passchier J, et al. Psy-chosocial factors and pregnancy outcome: a review with emphasis on methodological issues. J Psychosom Res 1995; 39 (5): 563-95
10. Steer RA, Scholl TO, Hediger ML, et al. Self-reported de-pression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45 (10): 1093-9
11. Preti A, Cardascia L, Zen T, et al. Obstetric complications in patients with depression: a population-based case-control study. J Affect Disord 2000; 61 (1-2): 101-6
12. McAnarney ER, Stevens-Simon C. Maternal psychological stress/depression and low birth weight: is there a relationship? Arch Pediatr Adolesc Med 1990; 144 (7): 789-92 (Pubitemid 20196676)
13. Field T, Diego M, Dieter J, et al. Prenatal depression effects on the fetus and the newborn. Infant Behav Dev 2004; 27 (2): 216-29
14. Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002; 155 (4): 293-301 (Pubitemid 34132046)
15. Dayan J, Creveuil C, Marks MN, et al. Prenatal depres-sion, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006; 68 (6): 938-46 (Pubitemid 44808720)
16. Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002; 156 (9): 797-802 (Pubitemid 35215759)
17. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63 (8): 898-906 (Pubitemid 44188483)
18. Austin MP, Lumley J. Antenatal screening for postnatal depression: a systematic review. Acta Psychiatr Scand 2003; 107 (1): 10-7 (Pubitemid 36092238)
19. Andrade SE, Raebel MA, Brown J, et al. Use of antide-pressant medications during pregnancy: a multisite study. Am J Ostet Gynecol 2008; 198 (2): 194.e1-5
20. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmcokinet 1993; 24 (3): 203-20 (Pubitemid 23094387)
21. Mant A, Rendle VA, Hall WD, et al. Making new choices about antidepressants in Australia: the long view 1975-2002. Med J Aust 2004; 181 (7 Suppl.): 21-4S
22. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety and pharmacoeconomics. J Psycho-pharmacol 1998; 12 (4 Suppl.): 55-87S
23. Nakhai-Pour HR, Broy P, Berard A. Use of antidepres-sants during pregnancy and the risk of spontaneous abortion. CMAJ 2010; 182 (10): 1031-7
24. Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000; 19 (6): 535-43
25. Chung TKH, Lau TK, Yip ASK, et al. Antepartum de-pressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63 (5): 830-4 (Pubitemid 32911013)
26. Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95 (4): 487-90 (Pubitemid 30139565)
27. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295 (5): 499-507 (Pubitemid 43200344)
28. Appleby L. Suicide during pregnancy and in the first postnatal year. BMJ 1991; 302 (6769): 137-40
29. Pearlstein T, Howard M, Salisbury A, et al. Postpartum depression. Am J Ostet Gynecol 2009; 200 (4): 357-64
30. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269 (17): 2246-8 (Pubitemid 23120281)
31. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335 (14): 1010-5 (Pubitemid 26338730)
32. Kulin NA, Pastuszak A, Sage SR, etal. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279 (8): 609-10 (Pubitemid 28110208)
33. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalo-pram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Ostet Gynecol 2005; 193 (6): 2004-9 (Pubitemid 41737626)
34. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66 (5): 695-705
35. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165 (6): 749-52 (Pubitemid 351810544)
36. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23 (6): 493-509
37. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89 (5): 713-8 (Pubitemid 27184852)
38. Irl C, Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf 2000; 22 (3): 169-77 (Pubitemid 30157577)
39. Kallen BAJ. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 2005; 45 (2): 44-51 (Pubitemid 41657755)
40. Stephansson O, Granath F, Svensson T. Drug use during pregnancy in Sweden: assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol 2011; 3: 43-50
41. Olsen J, Melbye M, Olsen SF, et al. The Danish National Birth Cohort: its background, structure and aim. Scand J Public Health 2001; 29 (4): 300-7 (Pubitemid 33731020)
42. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125: e600-8
43. Werler MM, Pober BR, Nelson K, et al. Reporting accu-racy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989; 129 (2): 415-21 (Pubitemid 19047007)
44. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16 (10): 1075-85 (Pubitemid 350020060)
45. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159 (12): 2055-61 (Pubitemid 35423865)
46. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Ob-stet Gynecol 2005; 106 (6): 1289-96 (Pubitemid 41668948)
47. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Ostet Gynecol 2006; 194 (4): 961-6
48. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17 (6): 701-4 (Pubitemid 44655607)
49. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16 (10): 1086-94 (Pubitemid 350020061)
50. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79 (4): 301-8 (Pubitemid 46980405)
51. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selec-tive serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339 (231): b3569
52. Oberlander TF, Warburton W, Misri S, et al. Major con-genital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83 (1): 68-76 (Pubitemid 351317794)
53. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-33
54. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356 (26): 2675-83 (Pubitemid 47001035)
55. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356 (26): 2684-92 (Pubitemid 47001036)
56. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85 (10): 837-41
57. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2: 29-36
58. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84 (1): 23-7
59. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80 (1): 18-27
60. Ramos E, St-Andre M, Rey E, et al. Duration of anti-depressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192 (5): 344-50 (Pubitemid 351692378)
61. Bakker MK, Kerstjens-Frederikse WS, Buys C, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88 (2): 94-100
62. GlaxoSmithKline. EPIP083 (preliminary report) epide-miology study: preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformations [online]. Available from URL: http://ctr.gsk.co.uk/summary/bupropion/studylist.asp [Accessed 2010 Jul 15]
63. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010; 88 (3): 159-70
64. Scialli AR. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res A Clin Mol Teratol 2010; 88 (3): 175-7
65. Berard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol 2010; 88 (3): 171-4
66. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29 (5): 918-26 (Pubitemid 47223423)
67. Sadler TW. Susceptible periods during embryogenesis of the heart and endocrine glands. Environ Health Perspect 2000; 108 (3 Suppl.): 555-61S
68. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antide-pressants: a multiple-treatments meta-analysis. Lancet 2009; 373 (9665): 746-58
69. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158 (4): 312-6 (Pubitemid 38451555)
70. Ferreira E, Carceller AM, Agogue C, et al. Effects of se-lective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119 (1): 52-9 (Pubitemid 46397842)
71. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163 (10): 949-54
72. Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166 (5): 557-66
73. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354 (6): 579-87 (Pubitemid 43209105)
74. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17 (8): 801-6
75. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multi-center prospective controlled study. Am J Psychiatry 2001; 158 (10): 1728-30 (Pubitemid 32923672)
76. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000 Nov 15; 48 (10): 996-1000
77. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18 (3): 246-52
78. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142 (4): 402-8 (Pubitemid 36521227)
79. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60 (7): 720-6 (Pubitemid 36818634)
80. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73 (4): 330-7 (Pubitemid 36403593)
81. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72 (2): 184-91 (Pubitemid 35034496)
82. Suri R, Altshuler L, Hendrick V, et al. The impact of de-pression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004; 7 (3): 193-200 (Pubitemid 38981242)
83. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29 (6): 555-60
84. Lewis AJ, Galbally M, Opie G, et al. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010; 44 (5): 482-7
85. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336 (4): 258-62 (Pubitemid 27044627)
86. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluox-etine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159 (11): 1889-95 (Pubitemid 35283255)
87. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113 (2): 368-75 (Pubitemid 38177090)
88. Costei AM, Kozer E, Ho T, et al. Perinatal outcome fol-lowing third trimester exposure to paroxetine. Arch Pe-diatr Adolesc Med 2002; 156 (11): 1129-32 (Pubitemid 36343460)
89. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008; 115 (2): 283-9 (Pubitemid 350233600)
90. Oberlander TF, Misri S, Fitzgerald C, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65 (2): 230-7
91. Lattimore KA, Donn SM, Kaciroti N, et al. Selective ser-otonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005; 25 (9): 595-604 (Pubitemid 43118131)
92. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Ob-stet Gynecol 2003; 188 (3): 812-5 (Pubitemid 36332456)
93. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160 (2): 173-6 (Pubitemid 43213863)
94. Galbally M, Lewis AJ, Lum J, et al. Serotonin dis-continuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009; 43 (9): 846-54
95. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293 (19): 2372-83 (Pubitemid 40676760)
96. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365 (9458): 482-7 (Pubitemid 40215730)
97. Wooltorton E. Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ 2006; 174 (11): 1555-6 (Pubitemid 43829508)
98. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010; 121 (6): 471-9
99. Yonkers KA, Wisner KL, Stewart DE, et al. The manage-ment of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31: 403-13.
100. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor anti-depressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161 (1): 22-9 (Pubitemid 46045459)
101. Misri S, Reebye P, Kendrick K, et al. Internalizing beha-viors in 4-year-old children exposed in utero to psycho-tropic medications. Am J Psychiatry 2006; 163 (6): 1026-32 (Pubitemid 44464489)
102. Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002 Apr; 51 (4): 443-53 (Pubitemid 34267314)
103. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005; 19 (7): 623-33 (Pubitemid 41058372)
104. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2005; 31 (1): 47-57 (Pubitemid 43250940)
105. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001; 56 (5): 479-85 (Pubitemid 34031783)
106. Winter C, Reutiman TJ, Folsom TD, et al. Dopamine and serotonin levels following prenatal viral infection in mouse: implications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol 2008; 18 (10): 712-6
107. Whitaker-Azmitia PM. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? Int J Dev Neurosci 2005; 23 (1): 75-83 (Pubitemid 40261239)
108. Rubinow DR. Antidepressant treatment during pregnancy: between Scylla and Charybdis. Am J Psychiatry 2006; 163 (6): 954-6 (Pubitemid 44464478)
109. Nutt DJ, Forshall S, Bell C, et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 1999; 9 (3 Suppl.): 81-6S
110. Rudberg I, Hermann M, Refsum H, et al. Serum con-centrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008; 64 (12): 1181-8
111. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3 (1): 13-37 (Pubitemid 34296308)
112. Yu BN, Chen GL, He N, et al. Pharmacokinetics of cita-lopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003; 31 (10): 1255-9 (Pubitemid 37152977)
113. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009; 10 (5): 520-9
114. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 1998; 12 (3 Suppl.): 5-20S
115. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004; 26 (6): 685-7 (Pubitemid 39579152)